Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with CpG oligonucleotide

ECI Vaccine IX 2024 -- Self-amplifying RNA (sa mRNA) formulated in lipid nanoparticles (LNPs) is a novel vaccine modality and is being used to develop a Marburg Virus vaccine comprising the Glycoprotein (MARV) sa mRNA. To evaluate whether TLR agonists will act as an adjuvant with the sa mRNA-LNP vaccines formulation development has been performed comprising MARV sa mRNA-LNPs encapsulating a CpG oligonucleotide (TLR 9 agonist). A design of experiment (DoE) approach was used to optimize the nucleic acid loading and the lead formulation was characterized to meet the anticipated critical quality attributes (CQAs).